PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Pa	perwork Reduction Act of 1995,	Application Number	lection of information unless it displays a valid OMB 09/529,654	
TRANSMITTAL FORM		Filing Date	April 18, 2000	~ <u> </u>
		First Named Inventor	James T. Loch III	TO TO
Ç.	all correspondence after initial f	Iing) Art Unit	1626 C	Z o
The Asset Is an objection and the same		Examiner Name	Sonya N. Wright	THE SOL
	Pages in This Submission	Attorney Docket Number	A2090-1P US	1800g
		ENCLOSURES (Check all	тпат арріу)	9)
Fee Trans	smittal Form	Drawing(s)	After Allowance Commun to Group	
Fee Attached X Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement		Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group	
		Petition	(Appeal Notice, Brief, Reply	y Brief)
		Petition to Convert to a Provisional Application	Proprietary Information	
		Power of Attorney, Revocation Change of Correspondence A	Status Letter Other Enclosure(s) (please Identify below):	
		Terminal Disclaimer		
		Request for Refund		
		CD, Number of CD(s)		
Certified Docume	Copy of Priority	Remarks		
	e to Missing Parts/ ete Application			
	Response to Missing Parts nder 37 CFR 1.52 or 1.53			
				-
	SIGNA	TURE OF APPLICANT, ATTO	PRNEY, OR AGENT	-
Firm or Individual	Kenneth F. Minche	11		
Signature	1247	I fell		
Date		es 202003		
, , , , , , , , , , , , , , , , , , ,	C	ERTIFICATE OF TRANSMISS		
I hereby certify that first class mail in a	t this correspondence is being f		sited with the United States Postal Service with suffice	ient postage as
Typed or printe	ed Frances Tou	tkaldjian		
		uce Moutain	Date FEB, 20	n 2nn3

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer U S Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



AstraZeneca Docket No. A2090 PUSO OFFICE

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application of:

Loch III, et al.

Application Number:

09/529,654

Filed: For:

April 18, 2000

Novel Arylkyl Amines of Sprofuropyridines

Useful in Therapy

Group Art Unit: 1626

Examiner: Wright, Sonya N.

Assistant Commissioner for Patents Washington, DC 20231

INTRODUCTORY COMMENTS

Sir:

Applicants hereby respond to a Final Office Action dated 11/29/2002 which set a three month period for filing a response. This response is filed within three months of the date of the aforementioned Notice.

In this response Applicants request amendment of the claims solely to put the amended claims in condition for allowance (see remarks below).

FEES

Any fees required for filing this response are to be charged to Deposit Account 26-0166.

AMENDMENT

In the Claims:

Applicants request cancellation of Claims 2-3, 6, 9-10, 13, 16, 42 and 43 all without prejudice.

Applicants request entry of AMENDED claims 1, 4, 5, 7, 8, 11, 12 and 14 as follows:

To share a share the sa